行情

ADRO

ADRO

Aduro Biotech
NASDAQ

实时行情|Nasdaq Last Sale

2.590
+0.030
+1.17%
交易中 11:12 08/11 EDT
开盘
2.570
昨收
2.560
最高
2.600
最低
2.470
成交量
15.06万
成交额
--
52周最高
4.040
52周最低
0.9011
市值
2.10亿
市盈率(TTM)
-3.2327
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ADRO价格均价为3.750,最高价位3.750,最低价为3.750。

EPS

ADRO 新闻

更多
Aduro Biotech EPS misses by $0.02, beats on revenue
Aduro Biotech (NASDAQ:ADRO): Q2 GAAP EPS of -$0.21 misses by $0.02. Revenue of $5.57M (+13.9% Y/Y) beats by $2.11M. Shares +1.4%. Press Release
seekingalpha · 08/04 01:42
Aduro Biotech (ADRO) Reports Q2 Loss, Tops Revenue Estimates
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -10.53% and 76.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/03 23:15
Aduro Biotech Q2 EPS $(0.21) Up From $(0.23) YoY, Sales $5.57M Up From $4.89M YoY
Aduro Biotech (NASDAQ:ADRO) reported quarterly losses of $(0.21) per share. This is a 8.7 percent increase over losses of $(0.23) per share from the same period last year. The company reported $5.57 million in sales
Benzinga · 08/03 20:26
Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results
BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducing Ligand (APRIL) and Stimulator of Interferon Genes (STING)
GlobeNewswire · 08/03 20:05
Hedge Funds Are Warming Up To Aduro BioTech Inc (ADRO)
Insider Monkey · 07/04 20:38
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy
GlobeNewswire · 06/24 13:15
Dosing underway in Aduro Bio's BION-1301 study for kidney disease
Seeking Alpha - Article · 06/24 13:10
Aduro Biotech Announces First Patient Dosed In Phase 1 Study Of BION-1301 In IgA Nephropathy
Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy BERKELEY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical
Benzinga · 06/24 12:16

所属板块

生物技术和医学研究
-0.45%
制药与医学研究
+0.14%

热门股票

代码
价格
涨跌幅

ADRO 简况

Aduro Biotech, Inc.是一家临床阶段的免疫治疗公司。该公司专注于发现、开发和销售转换治疗各种疾病的疗法。该公司已开发了三个技术平台,包括Live, Attenuated, Double-Deleted(LADD),干扰素基因刺激因子(STING)Pathway Activator和B选择单克隆抗体。其LADD候选产品包括CRS-207、ADU-623、ADU-741和ADU-214。其STING Activator候选产品包括ADU-S100。其LADD技术平台用于表达肿瘤相关抗原,以诱导特效和靶向免疫应答。其STING Pathway Activator平台用于激活细胞内STING受体,产生肿瘤特效免疫应答。其B选择单克隆抗体平台用于在研究和临床前开发中的各种免疫调节活动。
展开

微牛提供Aduro BioTech Inc(NASDAQ-ADRO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ADRO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ADRO股票基本功能。